142.54 USD
+1.19
0.84%
At close Feb 10, 4:00 PM EST
Pre-market
142.51
-0.03
0.02%
1 day
0.84%
5 days
1.03%
1 month
-4.22%
3 months
-17.14%
6 months
-29.10%
Year to date
-4.97%
1 year
-41.76%
5 years
-57.94%
10 years
-63.93%
 

About: Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Employees: 7,570

0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 10 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

1.69% less ownership

Funds ownership: 92.53% [Q2] → 90.84% (-1.69%) [Q3]

3% less funds holding

Funds holding: 921 [Q2] → 893 (-28) [Q3]

15% less first-time investments, than exits

New positions opened: 100 | Existing positions closed: 117

18% less capital invested

Capital invested by funds: $31.2B [Q2] → $25.5B (-$5.72B) [Q3]

24% less call options, than puts

Call options by funds: $216M | Put options by funds: $284M

27% less funds holding in top 10

Funds holding in top 10: 11 [Q2] → 8 (-3) [Q3]

29% less repeat investments, than reductions

Existing positions increased: 261 | Existing positions reduced: 370

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$138
3%
downside
Avg. target
$198
39%
upside
High target
$300
110%
upside

10 analyst ratings

positive
30%
neutral
70%
negative
0%
Citigroup
Geoff Meacham
41% 1-year accuracy
11 / 27 met price target
12%upside
$160
Neutral
Maintained
28 Jan 2025
Wells Fargo
Mohit Bansal
57% 1-year accuracy
13 / 23 met price target
16%upside
$165
Equal-Weight
Maintained
10 Jan 2025
Truist Securities
Srikripa Devarakonda
43% 1-year accuracy
15 / 35 met price target
54%upside
$220
Buy
Maintained
8 Jan 2025
Piper Sandler
Christopher Raymond
25% 1-year accuracy
8 / 32 met price target
3%downside
$138
Neutral
Downgraded
2 Jan 2025
BMO Capital
Evan Seigerman
53% 1-year accuracy
8 / 15 met price target
15%upside
$164
Market Perform
Downgraded
20 Dec 2024

Financial journalist opinion

Based on 24 articles about BIIB published over the past 30 days

Positive
Zacks Investment Research
17 hours ago
Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?
We focus on biotech stocks like VRTX, GILD, BIIB, ALNY and MRNA, which are scheduled to report this week.
Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?
Positive
Zacks Investment Research
3 days ago
Seeking Clues to Biogen (BIIB) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Biogen (BIIB), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
Seeking Clues to Biogen (BIIB) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Positive
Zacks Investment Research
5 days ago
Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth
Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth
Neutral
Zacks Investment Research
1 week ago
Biogen Stock Down on Regulatory Update in the EU for Alzheimer's Drug
The EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of BIIB/Eisai's Leqembi in the EU for early AD.
Biogen Stock Down on Regulatory Update in the EU for Alzheimer's Drug
Neutral
Reuters
1 week ago
Europe to review safety data for Eisai-Biogen Alzheimer's drug
The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's Alzheimer's drug Leqembi, the agency said on Friday.
Europe to review safety data for Eisai-Biogen Alzheimer's drug
Neutral
GlobeNewsWire
1 week ago
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union
TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as treatment for early AD (mild cognitive impairment due to Alzheimer's disease (AD) and mild AD) in the European Union.
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union
Positive
Zacks Investment Research
1 week ago
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
Positive
Zacks Investment Research
2 weeks ago
BIIB Secures FDA Nod for Monthly Maintenance Dosing of Alzheimer's Drug
The FDA's approval is based on simulation data from multiple studies showing that maintenance dosing with Biogen???s Leqembi every four weeks prolongs biomarker benefits.
BIIB Secures FDA Nod for Monthly Maintenance Dosing of Alzheimer's Drug
Negative
Reuters
2 weeks ago
Sage rejects Biogen's $469 million takeover offer
Sage Therapeutics said on Monday that its board has unanimously rejected the takeover offer it received from Biogen.
Sage rejects Biogen's $469 million takeover offer
Positive
Reuters
2 weeks ago
US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug
The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's Alzheimer's drug Leqembi, the companies said on Monday.
US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug
Charts implemented using Lightweight Charts™